30 closest matches · ranked by relevance
Neoplasms
Primary: Maximum Tolerated Dose (MTD), Defined as Maximum Dose at Which the Incidence of Dose Limiting Toxicities (DLTs) During Cycle 1 is Below 20% — 800 mg BID
Advanced Malignant Solid Neoplasm · Cholangiocarcinoma · Metastatic Malignant Solid Neoplasm
Primary: Overall Response Rate (ORR) — 13.3 percentage of participants
Hepatocellular Carcinoma (HCC) · Solid Malignancies
Primary: Number of Participants With Dose-limiting Toxicity (DLT): Phase I Only — 10.0; 0; 0; 4.3 Percentage of participants
Head and Neck Neoplasm · Prostatic Neoplasm · Pancreatic Neoplasm
Primary: Number of Participants With First Cycle Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 participants
Advanced Lymphoma · Advanced Malignant Solid Neoplasm · Hematopoietic and Lymphoid Cell Neoplasm
Primary: Overall Response Rate (ORR) — 8 percentage of participants
FGFR1 Gene Amplification · FGFR1 Gene Mutation · FGFR2 Gene Amplification
Primary: Objective Response Rate (Confirmed and Unconfirmed, Complete and Partial) — 7 percentage of participants
Metastatic Breast Cancer
Primary: Number of Participants With Dose Limiting Toxicities (DLT) in the First Cycle for the Determination of the Maximum Tolerated Dose (MTD) — 0; 0; 2 participants
Neoplasms
Primary: Number of Participants With Non-serious Adverse Events (AEs) and Serious AEs (SAEs) — 3; 3; 14; 3 Participants
Colorectal Cancer
Primary: Assessment of Early Response by 18F-Fluorodeoxyglucose(18F-FDG) Positron Emission Tomography/Computed Tomography (PET/CT) on Day 21 of Regorafenib Compared With the…
Malignant Hepatobiliary Neoplasm
Primary: Clinical Benefit Rate (Percentage), Which Includes Confirmed Tumor Response (Complete Response [CR] or Partial Response [PR]) or Stable Disease (SD) — 45.5 percentage of…
Cholangiocarcinoma · Urothelial Cancer · Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR Tumors
Primary: Phase 1: Dose Escalation-Maximum Tolerated Dose (MTD) — NA; 20 Milligrams
Head and Neck Neoplasms · Pheochromocytoma · Colorectal Neoplasms
Primary: Response Rate — 0; 0; 26; 11 Participants
Renal Cell Carcinoma
Primary: Percent Change From Baseline in Activated and Memory T Cells — NA; NA; NA; NA Percentage
Gastrointestinal Stromal Tumors
Primary: Disease Control Rate (DCR; OR + Stable Disease) — 13 Percentage of participants
Tumors
Primary: Part 1: Number of Participants With Dose-limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Intrahepatic Cholangiocarcinoma · Combined Hepatocellular and Cholangiocarcinoma
Primary: Substudy 1: Objective Response Rate (ORR) — 22.3 Percentage of participants
Malignant Neoplasm
Primary: Overall Response, Defined as the Number of Patients Who Achieve Any Response According to Disease Type in the First 6 Courses of Treatment — 1; 0 Participants
Solid Tumor
Primary: Number of Patients With Drug-related Treatment-emergent Adverse Events (TEAEs) — 3; 1; 1; 11 Participants
Renal Cell Cancer
Primary: Metabolic Response — 5 participants
Recurrent Glioblastoma or Other Glioma Subtypes
Primary: Progression Free Survival — 1.7 months
Carcinoma, Non-Small-Cell Lung · Non-Small Cell Lung Cancer · Nonsmall Cell Lung Cancer
Primary: Response Rate (RR) — 3 Participants
Tumor Pathway Activations Inhibited by Dovitinib
Primary: Clinical Benefit Rate (CBR) — 0; 1; 10; 11 number of participants
Non-Small Cell Lung Cancer ALK-positive · Non-Small Cell Lung Cancer c-Met Dependent · Non-Small Cell Lung Cancer ROS Marker Positive
Primary: Dose-Escalation Cohort: Maximum Tolerated Dose (MTD) of Crizotinib — 250; 250; 250; 250 milligram
Advanced Gastrointestinal Stromal Tumors
Primary: Number of Participants With Non Progression at 4 Months — 3 Participants
Solid Tumors and Advanced Endometrial Cancer · Endometrial Cancer · Second-line Treatment
Primary: Progression Free Survival (PFS) Rate — 31.8; 29.0 Percentage of participants
Advanced Solid Tumors · Metastatic Colon Cancer · Metastatic Breast Cancer
Primary: Dose Escalation Phase: Number of Participants With Dose-limiting Toxicities (DLTs) — 1; 0 Participants
Recurrent Non-small Cell Lung Cancer · Squamous Cell Lung Cancer
Primary: Maximum Tolerated Dose (MTD) of FGFR Inhibitor AZD4547 — NA mg
Advanced Solid Tumor
Primary: Broad Panel and Pediatric Cohorts: Objective Response Rate (ORR) Based on Response Assessment in Neuro-Oncology (RANO) as Assessed by Independent Review Committee (IRC)…
Breast Cancer
Primary: Change From Baseline in 18F-FLT-PET Mean Standardized Uptake Value (SUVmean) After the First Cycle of Standard of Care (SOC) Neo-adjuvant Chemotherapy. — 2.79; 1.78…
Glioblastoma Multiforme
Primary: Number of Phase I Patients Receiving 60mg or 80mg BKM120 Experiencing a Dose-Limiting Toxicity (DLT) to Determine the Optimal Dosage — 0; 3 Participants